ReviewClinical and vaccine immunology : CVI2015
Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now.
Review in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Estimating the global and regional burden of meningitis in children caused byJournal of global health · 2022Pooled it
- A bacterial pangenome association study identifies a role for polyamine metabolism and alkaline tolerance in middle ear infections.PLoS pathogens · 2026Article
- Lipidated Protein D vaccination elicits humoral and cellular responses and protects mice against challenge with non-typeableInfection and immunity · 2026Article
- Multi-Antigen Protein Vaccine Confers Protection in a Murine Model Against IntranasalVaccines · 2026Article
- Characterization of a conserved outer-membrane protein in non-typeableMicrobiology spectrum · 2026Article
- Genetic population structure of Haemophilus influenzae at local and global scales.Nature microbiology · 2025Article
- Exposure to bacterial lipopolysaccharide aggravates H1N1-mediated lung immunopathology via neutrophil extracellular trap formation.Scientific reports · 2025Article
- Exploiting haem-iron dependence of nontypeableFrontiers in cellular and infection microbiology · 2025Review
- Bronchial epithelial cell-derived extracellular vesicles drive inflammasome activation andFrontiers in immunology · 2025Article
- Article
- Potential role of the antimicrobial peptide Tachyplesin III in regulating nontypeable Haemophilus influenzae-induced inflammation in airway epithelial cells.Archives of microbiology · 2024Article
- Genomic classification and antimicrobial resistance profiling of Streptococcus pneumoniae and Haemophilus influenza isolates associated with paediatric otitis media and upper respiratory infection.BMC infectious diseases · 2023Article
- Antigen-specific memory Th17 cells promote cross-protection against nontypeable Haemophilus influenzae after mild influenza A virus infection.Mucosal immunology · 2023Article
- Article
- Haemophilus influenzae Protein D antibody suppression in a multi-component vaccine formulation.FEBS open bio · 2022Article
- A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable.American journal of respiratory and critical care medicine · 2022Review
- Lipidation ofInfection and immunity · 2022Article
- Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.BMC infectious diseases · 2022Article
- Article
- Australian Aboriginal Otitis-Prone Children Produce High-Quality Serum IgG to Putative NontypeableFrontiers in cellular and infection microbiology · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Infections due to nontypeable Haemophilus influenzae result in enormous global morbidity in two clinical settings: otitis media in children and respiratory tract infections in adults with chronic obstructive pulmonary disease (COPD). Recurrent otitis media affects up to 20% of children and results in hearing loss, delays in speech and language development and, in developing countries, chronic suppurative otitis media. Infections in people with COPD result in clinic and emergency room visits, hospital admissions, and respiratory failure. An effective vaccine would prevent morbidity, help control health care costs, and reduce antibiotic use, a major contributor to the global crisis in bacterial antibiotic resistance. The widespread use of the pneumococcal conjugate vaccines is causing a relative increase in H. influenzae otitis media. The partial protection against H. influenzae otitis media induced by the pneumococcal H. influenzae protein D conjugate vaccine represents a proof of principle of the feasibility of a vaccine for nontypeable H. influenzae. An ideal vaccine antigen should be conserved among strains, have abundant epitopes on the bacterial surface, be immunogenic, and induce protective immune responses. Several surface proteins of H. influenzae have been identified as potential vaccine candidates and are in various stages of development. With continued research, progress toward a broadly effective vaccine to prevent infections caused by nontypeable H. influenzae is expected over the next several years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.